Superantigens, conventional antigens and the etiology of Kawasaki syndrome

Pediatric Infectious Disease Journal

Volumn 19, Issue 2, 2000, Pages 91-94

  Meissner, H Cody ^a,c   Leung, Donald Y M ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Etiology; Kawasaki syndrome; Superantigen

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SUPERANTIGEN;

CELL PROLIFERATION; GENETIC PREDISPOSITION; INFECTION RISK; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MUCOCUTANEOUS LYMPH NODE SYNDROME; NOTE; PREVALENCE; PRIORITY JOURNAL; T LYMPHOCYTE RECEPTOR GENE; THEORY;

ANTIGENS, BACTERIAL; CHILD; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS;

EID: 0033977904     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200002000-00001     Document Type: Note

References (27)

1. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776-80.
2. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995;8:411-26.
3. Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992; 89:4066-70.
4. Abe J, Kotzin BL, Meissner HC, et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 1993;177:791-6.
5. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995;72:308-11.
6. Yamashiro Y, Nagata S, Oguchi S, Shimizu T. Selective increase of V beta 2 T cells in the small intestine mucosa in Kawasaki disease. Pediatr Res 1996;39:264-6.
7. Yoshioka T, Matsutani T, Iwagami S, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology 1999;96:465-72.
8. Pietra BA, De Inocencio J, Giannini EH, Hirsch R. T cell receptor V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol 1994;153:1881-8.
9. Barron KS, Shulman ST, Rowley A, et al. Report of the National Institute of Health on Kawasaki disease. J Rheum 1999;26:170-90.
10. Choi BY, Lafferty JA, Clements JR, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990;172:981-4.
11. Wiesenthal AM, Todd JK. Toxic shock syndrome in children aged 10 years or less. Pediatrics 1984;74:112-7.
12. Davies HD, Kirk V, Jadavji T, Kotzin BL. Simultaneous presentation of Kawasaki disease and toxic syndrome in an adolescent male. Pediatr Infect Dis J 1996;155:1136-7.
13. Hofer MF, Newell K, Duke RC, Schlievert PM, Freed JH, Leung DY. Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis. Proc Natl Acad Sci USA 1996;93:5425-30.
14. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342:1385-7.
15. Terai M, Miwa K, Williams T, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995;172:558-61.
16. Lowy FD. Staphylococcus aureus infections. NEJM 1998;339: 520-32.
17. Wann ER, Fehringer AP, Ezepchuk V, et al. Staphylococcus aureus isolates from patients with Kawasaki disease express high levels of protein A. Infect Immun 1999;67:4737-43.
18. Holl M, Hoyt L, Fertieri P, Schlievert PM, Jensen HB. Kawasaki syndrome-like illness associated with infection caused by enterotoxin-B secreting Staphylococcus aureus. Clin Infect Dis 1999;29:586-9.
19. Masuda K, Takei S, Nomura Y, Imanaka H, Sameshima K, Yoshinaga M. Transient low T cell response to streptococcal pyrogenic exotoxin-C in patients with Kawasaki disease. Pediatr Res 1998;44:27-31.
20. Sutkowski N, Palkama, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT. An Epstein-Barr virus-associated superantigen. J Exp Med 1996;184:971-80.
21. Stolz SJ, Davis JP, Vergeront JM, et al. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis 1988;151: 883-9.
22. Meissner HC, Schlievert PM, Leung DYM. Mechanisms of immunoglobular action: observations on Kawasaki syndrome and RSV prophylaxis. Immunol Rev 1994;139:109-23.
23. Rowley AM. The etiology of Kawasaki disease: superantigen or conventional antigen? Pediatr Infect Dis J 1999;18:69-70.
24. + T cells in Kawasaki disease. J Immunol 1997;159:481-6.
25. Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946-55.
26. Marrock P, Kapplen J. The staphylococcal enterotoxins and their relatives. Science 1990;248:1066-74.
27. Leung DY, Gately M, Taumble A, Ferguson-Darndle B, Schievert PM, Picken LJ. Bacterial superantigens induce T-cell expression of the skin selective homing receptor, the cutaneous lymphocyte associated antigen via stimulation of interleukin 12 production. J Exp Med 1995;181:747-75.